Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Opening Session Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Aug

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Opening Session Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Large Multicenter Study Evaluates LITT for Primary and Metastatic Brain Tumors

Tissue-Free ctDNA Assay May Help Identify Recurrence Risk in Early Triple-Negative Breast Cancer

Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer

In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles

cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions